PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Possibility of performing diagnostic laparoscopy or cytoreductive surgery.
Presence of homologous recombination deficiency (HRD).
No contraindications to chemotherapy, or bevacizumab.
Signed informed consent to participate in the study.
You may not be if
Presence of another active malignant invasive neoplasm.
Pregnancy or lactation period.
Disease progression during treatment.
Clareo Health | PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
